The Long COVID Treatment Trial

NCT07128082 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether a treatment can help reduce fatigue in adults who have Long COVID.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 1,000 people

Who can join Ages 18+ · all sexes

Timeline Started 2025-10 · est. completion 2026-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07128082 ↗

Description as written by the study sponsor.

The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us to measure the effect of the treatment by having half of the participants take the medication and half take a placebo that has no medication. Participants will take the medication (or placebo) they are given and complete study surveys for 12 months. All of the study tasks are done remotely from the comfort of a participants home.

Treatments tested

Tirzepatide Drug

The treatment group will receive the study medication (tirzepatide) for a 12 month period starting with a 2.5mg dose once a week.
Placebo Drug

Participants in the control group will receive a placebo instead of active study medication for a 12 month period.

Main thing measured	Primary Objective 1: Changes in fatigue severity score, measured by Fatigue Severity Scale (FSS)
Sponsor	Scripps Translational Science Institute
Conditions studied	Long COVID
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07128082 ↗